Preliminary results of the phase I BLOOM study of 38 EGFR-mutant NSCLC with BM or leptomeningeal metastasis (LM) treated with AZD3759 showed an intracranial ORR of 63% and extracranial ORR of 50% (74). Here, EGFR is linked to non-small cell lung carcinoma.